A large portion of the new customers receiving prescriptions for Novo Nordisk's weight-loss pill have previously used the company's drug Wegovy or competitor Eli Lilly's Zepbound, a study shows. Photo: Reuters/Reuters
Novo’s weight loss pill attracts rival’s customers
Nearly 16 percent of patients prescribed Novo Nordisk’s new weight loss pill previously used Eli Lilly’s injectable drug Zepbound, according to a Truveta study of 8,762 patients. As the first oral GLP-1 treatment for obesity, the pill attracts new patients, with 36.1 percent of users having...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?